Ricerca avanzata

Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > Articoli online first > The Journal of Cardiovascular Surgery 2016 Nov 23

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOTHE JOURNAL OF CARDIOVASCULAR SURGERY

Rivista di Chirurgia Cardiaca, Vascolare e Toracica


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632

 

The Journal of Cardiovascular Surgery 2016 Nov 23

Evaluation of a 6-year old multicentric standard endovascular treatment of critical limb ischemia in the drug-eluting era

Vincenzo BRIZZI, Caroline CARADU, Xavier BERARD, Gerard SASSOUST, Dominique MIDY, Eric DUCASSE

1 Unit of Vascular Surgery, Hopital Tripode, Universitary Hospital of Bordeaux, Université de Bordeaux, Bordeaux, France

BACKGROUND: There has been increasing evidence to support the endovascular- first approach in the treatment of below the knee (BTK) lesions. Plain Old Balloon Angioplasty (POBA), with bailout bare-metal stent scaffolding in case of flow limiting dissection or recoil, have been considered the standard treatment of choice but industries are continually developing innovative equipment and dedicated technologies, such as drug-eluting platforms whose use is increasingly extended, despite significant costs and lack of high-quality evidence to support a well- established strategy. This study’s objective was to analyze the 6-year old results of “standard” endovascular treatment of BTK lesions in the drug-eluting era.
METHODS: From August 2008 to February 2010, 21 French speaking European centers consecutively enrolled critical limb ischemia (CLI) patients with BTK lesions treated endovascularly into the ANgioplastie JambièrE (ANJE) registry. Primary endpoint was 1-year limb salvage, a subgroup analysis was performed to compare POBA, bare nitinol stents and balloon expandable stents (BESs).
RESULTS: Of the 282 patients included (61.7%, men, mean age 75.8 ± 10.0 years), 53.5% were diabetic and 29.4% presented with chronic kidney disease. At 1 year, complete wound healing was described in 187 patients (82.7%), the overall limb salvage rate was 94.0% with a survival rates of 89.2%. The primary and secondary patency rates were 84.5% and 91.7% respectively with significantly lower primary patency rates after stenting (80.6% vs 87.6% after POBA; P = .043). The rate of freedom from target lesion revascularization (TLR) was 86.3% with significantly lower rates after stenting (81.8% vs 89.9% after POBA; P = .01). The subgroup analysis showed no significant difference between nitinol stents, BESs and POBA in terms of limb salvage and survival rates, however, primary and secondary patency rates were significantly lower after BESs (primary and secondary patency rates of 84.0% after nitinol stents vs 77.4% after BES vs 87.6% after POBA; P = .012 and 93.0% vs 77.4% vs 87.6%; P = .003 respectively), as well as freedom from TLR rates (82.3% vs 81.2% vs 89.9%; P = .04).
CONCLUSIONS: In the drug eluting era, the endovascular first approach of BTK lesions based on POBA with bailout spot stenting is feasible, affordable but most importantly remains effective and should be the first line strategy until the place of drug eluting stents is precisely defined.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina